Back to results
US 7,888,320 B2Granted
Composition for treating cancer adapted for intra-tumoral administration and uses thereof
AssigneeCentre National de la Recherche Scientifique (CNRS)
InventorsAbdelilah Wakkach, Claudine Blin-Wakkach, David Momier, Georges Carle
Life of this patent
Estimating the term…
Abstract
A composition is adapted for intra-tumoral administration of a subject suffering from cancer, whereby administration of the composition to the subject induces IMC differentiation by neutralizing a factor implicated in a DC differentiation defect.
Claims5
A method of treating cancer comprising:
- intratumorally administering a therapeutically effective amount of a composition comprising:
- (i) a protein able to neutralize the binding of IL-10 to its receptor that is a soluble receptor for IL-10, an IL-3 protein, and a Toll-like receptor ligand, or
- (ii) a nucleic acid encoding the protein able to neutralize the binding of IL-10 to its receptor that is a soluble receptor for IL-10 and encoding the IL-3 protein, and a Toll-like receptor ligand, or
- (iii) a cell transformed by the nucleic acid (ii) and expressing the protein able to neutralize the binding of IL-10 to its receptor that is a soluble receptor for IL-10 and expressing the IL-3 protein, and a Toll-like receptor ligand, to a patient.
1 more element
A method of treating cancer comprising:
- intratumorally administering a therapeutically effective amount of a composition comprising:
- (i) a protein able to neutralize the binding of IL-10 to its receptor, and an IL-3 protein, or
- (ii) a nucleic acid encoding a protein able to neutralize the binding of IL-10 to its receptor and encoding an IL-3 protein, or
- (iii) a cell transformed by the nucleic acid (ii) and expressing a protein able to neutralize the binding of IL-10 to its receptor and expressing an IL-3 protein, to a patient.
1 more element
A method of treating cancer comprising:
- intratumorally administering a therapeutically effective amount of a composition comprising:
- (i) a nucleic acid encoding a protein able to neutralize the binding of IL-10 to its receptor wherein the nucleic acid comprises SEQ ID NO:
- 1, or
- (ii) a cell transformed by the nucleic acid (i) and expressing a protein able to neutralize the binding of IL-10 to its receptor,
- to a patient, wherein the composition optionally comprises a molecule able to potentiate dendritic cell differentiation selected from the group consisting of a cytokine and a Toll-like receptor ligand.
2 more elements
Dependencies are inferred from the claim text.